lymphoma

KEI and UACT Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment

Posted on by KEI Staff

Update: The NIH sent a response to our comments, available here. The response fails to address the glaring lack of information available regarding Retargeted Therapeutics. On June 8, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT)… Continue Reading →

Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma (and NIH Response)

Posted on by Kathryn Ardizzone

(UPDATE: As noted in the comments below, the NIH provided a response to the joint comments submitted on September 5, 2019, well in advance of the close of the comment period on September 15, 2019) On September 19, 2019, Knowledge… Continue Reading →